Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.

Yaturu S, DjeDjos S, Alferos G, Deprisco C.

Prostate Cancer Prostatic Dis. 2006;9(1):35-8.

PMID:
16276350
2.

Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.

Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D.

J Clin Densitom. 2006 Oct-Dec;9(4):431-7. Epub 2006 Sep 6.

PMID:
17097529
3.

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.

Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.

Urology. 2007 Jul;70(1):122-6.

PMID:
17656221
4.

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.

J Urol. 2006 Sep;176(3):972-8; discussion 978.

PMID:
16890673
5.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

6.

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.

Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.

Int J Urol. 2007 Dec;14(12):1071-5.

7.

Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.

Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.

BJU Int. 2007 Jul;100(1):70-5.

8.

The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.

Smith MR.

Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5. Review.

PMID:
15202584
10.
11.
12.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
13.

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Ross RW, Small EJ.

J Urol. 2002 May;167(5):1952-6. Review.

PMID:
11956415
15.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
16.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
17.

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

J Urol. 2006 May;175(5):1679-83; discussion 1683.

PMID:
16600728
18.

Androgen deprivation therapy for prostate cancer results in significant loss of bone density.

Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA.

Urology. 1999 Oct;54(4):607-11.

PMID:
10510915
19.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.

N Engl J Med. 2001 Sep 27;345(13):948-55.

20.

Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.

Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y, Kadono Y, Takashima M, Koh E, Namiki M.

Urology. 2009 Jun;73(6):1342-6. doi: 10.1016/j.urology.2009.01.046. Epub 2009 Apr 15.

PMID:
19371939

Supplemental Content

Support Center